Evaluation of efficacy of Lactogum and coldanese on prevention of flu-like symptoms

Evaluation of the effectiveness of Lactogum and Coldanese in preventing flu-like symptoms: A cluster randomized phase 3 clinical trial without blinding.

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20231214060363N1

Enrollment

2000

Registered

2024-07-17

Start date

2023-08-23

Completion date

Unknown

Last updated

2024-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Condition 1: Fever of other and unknown origin. Condition 2: Diarrhea. Condition 3: pharyngitis. Condition 4: Cough. Condition 5: rhinitis. Condition 6: Nausea and vomiting. Condition 7: flu-like symptoms. Fever of other and unknown origin Diarrhea, unspecified Acute pharyngitis, unspecified Cough Vasomotor and allergic rhinitis Nausea and vomiting Influenza due to unidentified influenza virus with other respiratory manifestations

Interventions

Intervention 1: first Intervention group: The group receiving Coldaniz Plus® nasal spray 3 times per day for Maximum of 10 day . Intervention 2: second Intervention group: The group receiving Lactogum

Eligibility

Sex/Gender

All

Age

16 Years to 70 Years

Inclusion criteria

Inclusion criteria: age range was 16 to 70 years old healthcare workers and members of therapeutic Mawkibs

Exclusion criteria

Exclusion criteria: Severe cardiovascular, endocrinological, respiratory, and gastrointestinal diseases Pregnancy Irritable bowel syndrome, active ulcerative colitis, or short bowel syndrome Known hypersensitivity or allergy to any component of the test products Severe deviation of the nasal septum, presence of nasal polyps, or other non-infectious conditions leading to nasal blockage Recent treatment of the common cold that, in the opinion of the investigator, may influence symptoms Immunodeficiency

Design outcomes

Primary

Measure	Time frame
Fever. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Diarrhea. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Pharyngitis. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Cough. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Rhinitis. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Nausea and vomiting. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.	—

Measure

Time frame

Fever. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Diarrhea. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Pharyngitis. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Cough. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Rhinitis. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.;Nausea and vomiting. Timepoint: Day 25, 35, and 45 after the intervention. Method of measurement: asking the patient and filling the checklist.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMostafa Ghanei

Bagheiat-allah University of Medical Sciences

mghaneister@gmail.com+98 21 8860 0067

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026